New migraine drug: A neurologist explains how it works

Published: May 31st, 2018

Category: News and Events

Author:  Assistant Professor of Neurology, University of Florida

The FDA announced approval on May 17 of a novel preventive treatment for migraine headaches. Aimovig is the first in a new class of migraine-specific drugs that works by blocking an action of a protein that is increased in people with migraine during headache attacks.

A migraine is a chronic disorder of the brain with recurrent severe attacks, from one or two times a year to nearly daily. The main feature of these attacks is severe headache. Other common features are nausea or even vomiting. Many people have sensitivity to light, odors or sounds and are unable to carry on daily activity.

As a neurologist who studies and treats migraine, I am encouraged by the efficacy of this new drug and others that target the same protein. But there are limitations

To learn more read the full article online in The Conversation